Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model DOI Creative Commons
Andrea Manni, Yuan‐Wan Sun, Todd D. Schell

и другие.

Pharmaceuticals, Год журнала: 2023, Номер 16(10), С. 1422 - 1422

Опубликована: Окт. 6, 2023

Immunotherapy targeting program cell death protein 1 (PD-1) in addition to chemotherapy has improved the survival of triple-negative breast cancer (TNBC) patients. However, development resistance and toxicity remain significant problems. Using translationally relevant 4T1 mouse model TNBC, we report here that dietary administration phytochemical quercetin enhanced antitumor action Cyclophosphamide, a cytotoxic drug with immunogenic effects is part combination used TNBC. We observed favorably modified host fecal microbiome by enriching species such as Akkermansia muciniphilia, which been shown improve response anti-PD-1 therapy. also show and, greater extent, Cyclophosphamide increased systemic frequency T cells NK cells. In addition, alone reduced Treg, consistent an immune response. On other hand, did not significantly alter microbiome, suggesting complementarity between microbiome- immune-mediated mechanisms potentiating quercetin. Overall, these results support potential for microbiota-centered intervention overcome chemoimmunotherapy

Язык: Английский

Advances in immunotherapy for triple-negative breast cancer DOI Creative Commons
Yang Liu,

Yueting Hu,

Jinqi Xue

и другие.

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Сен. 2, 2023

Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on editing, enhances antigenicity of cells and increases tumoricidal effect It also suppresses immunosuppressive molecules, activates or restores function, anti-tumor responses, inhibits growth f cell. This offers possibility reducing mortality in triple-negative breast cancer (TNBC).Immunotherapy approaches for TNBC have been diversified recent years, with breakthroughs this entity. Research checkpoint inhibitors (ICIs) made it possible identify different molecular subtypes formulate individualized schedules. review highlights unique microenvironment integrates analyzes advances ICI therapy. discusses strategies combination ICIs chemotherapy, radiation therapy, targeted emerging methods such nanotechnology, ribonucleic acid vaccines, gene Currently, numerous ongoing completed clinical trials are exploring utilization conjunction existing modalities TNBC. The objective these investigations assess effectiveness various combined determine most effective regimens patients TNBC.This provides insights into used overcome drug resistance immunotherapy, explores directions development

Язык: Английский

Процитировано

140

Towards targeting the breast cancer immune microenvironment DOI
Michael A. Harris, Peter Savas, Balaji Virassamy

и другие.

Nature reviews. Cancer, Год журнала: 2024, Номер 24(8), С. 554 - 577

Опубликована: Июль 5, 2024

Язык: Английский

Процитировано

73

Forks in the road for CAR T and CAR NK cell cancer therapies DOI
Oula K. Dagher, Avery D. Posey

Nature Immunology, Год журнала: 2023, Номер 24(12), С. 1994 - 2007

Опубликована: Ноя. 27, 2023

Язык: Английский

Процитировано

71

Cold and hot tumors: from molecular mechanisms to targeted therapy DOI Creative Commons
Bo Wu, Bo Zhang, Bowen Li

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Окт. 18, 2024

Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment therapy, only a minority patients exhibit positive response to it. In with solid tumors, those who respond well typically demonstrate an active profile referred as "hot" (immune-inflamed) phenotype. On other hand, non-responsive may distinct "cold" (immune-desert) phenotype, differing from features tumors. Additionally, there is more nuanced "excluded" positioned between and categories, known type. Effective differentiation understanding intrinsic factors, characteristics, TME, external factors are critical for predicting results. It widely accepted that therapy exerts profound effect on limited efficacy against or "altered" necessitating combinations therapeutic modalities enhance cell infiltration into tissue convert tumors ones. Therefore, aligning traits this review systematically delineates respective influencing extensively discusses varied approaches drug targets based assess efficacy.

Язык: Английский

Процитировано

68

LncFASA promotes cancer ferroptosis via modulating PRDX1 phase separation DOI
Fan Xiao, Fangzhou Liu, Xiang Wang

и другие.

Science China Life Sciences, Год журнала: 2023, Номер 67(3), С. 488 - 503

Опубликована: Ноя. 10, 2023

Язык: Английский

Процитировано

25

Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies DOI Creative Commons
Jun He,

Zejing Qiu,

Jingjing Fan

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Авг. 14, 2024

Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the tolerant persister (DTP) cell phenotype is attracting more and attention giving a predominant non-genetic role in cancer therapy The DTP characterized by quiescent or slow-cell-cycle reversible state subpopulation inert specialization to stimuli, which tolerates exposure some extent through interaction multiple underlying recovering growth proliferation after withdrawal, ultimately leading treatment resistance recurrence. Therefore, targeting cells anticipated provide new opportunities for patients, although our current knowledge these remains limited. In this review, we comprehensive overview formation characteristics cells, investigate potential drugs (including preclinical drugs, novel use old natural products) based on different medicine models, discuss necessity feasibility anti-DTP therapy, related application forms, future issues that will need be addressed advance emerging field towards clinical applications. Nonetheless, understanding functions may enable us develop effective improve outcomes patients.

Язык: Английский

Процитировано

18

The intersection of the nervous system and breast cancer DOI
Yutong Liu,

Shiqi Yin,

Guanyu Lu

и другие.

Cancer Letters, Год журнала: 2024, Номер 598, С. 217132 - 217132

Опубликована: Июль 24, 2024

Язык: Английский

Процитировано

13

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer DOI Open Access
Gyöngyi Munkácsy, Libero Santarpia,

Balázs Győrffy

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(8), С. 6945 - 6945

Опубликована: Апрель 8, 2023

Triple-negative breast cancer (TNBC) is the most aggressive subtype of cancer, with clinical features high metastatic potential, susceptibility to relapse, and poor prognosis. TNBC lacks expression estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2). It characterized by genomic transcriptional heterogeneity a tumor microenvironment (TME) presence levels stromal tumor-infiltrating lymphocytes (TILs), immunogenicity, an important immunosuppressive landscape. Recent evidence suggests that metabolic changes in TME play key role molding development impacting immune cell fractions, composition, activation. Hence, complex inter-talk between signaling exists, highlighting possibility uncovering investigating novel therapeutic targets. A better understanding interaction cells, underlying molecular mechanisms cell–cell communication signaling, may uncover additional targets for strategies treatment. In this review, we aim discuss reprogramming, linking these potential targetable generate new, physical science-inspired translational insights cure TNBC.

Язык: Английский

Процитировано

19

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review DOI Creative Commons
Lucía Serrano-García, Beatriz Jávega, Antonio Llombart‐Cussac

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 13, 2024

Triple-negative breast cancer (TNBC) is an aggressive subtype of characterized by the absence progesterone and estrogen receptors low (or absent) HER2 expression. TNBC accounts for 15-20% all cancers. It associated with younger age, a higher mutational burden, increased risk recurrence mortality. Standard treatment primarily relies on cytotoxic agents, such as taxanes, anthracyclines, platinum compounds both early advanced stages disease. Several targeted therapies, including bevacizumab sunitinib, have failed to demonstrate significant clinical benefit in TNBC. The emergence immune checkpoint inhibitors (ICI) has revolutionized treatment. By stimulating system, ICIs induce durable anti-tumor response across various solid tumors. particularly promising target due levels tumor-infiltrating lymphocytes (TIL), PD-L1 expression, which generates tumor-specific neoantigens that activate cells. administered monotherapy yields only modest response; however, rates significantly improve when are combined tumors expressing PD-L1. Pembrolizumab approved use combination standard chemotherapy. However, more research needed identify potent biomarkers, better elucidate synergism other agents. In this review, we explore challenges immunotherapy TNBC, examining mechanisms tumor progression mediated cells within microenvironment, signaling pathways involved primary acquired resistance. Finally, provide comprehensive overview ongoing trials underway investigate novel immune-targeted therapies

Язык: Английский

Процитировано

7

The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy DOI Creative Commons
Ruonan Li, Lili Cao

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Май 18, 2023

The treatment outcome of breast cancer is closely related to estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) expression. Triple-negative (TNBC) lacking ER, PR, HER2 expression has limited options a poor prognosis. Tumor-infiltrating lymphocytes (TILs) play role in promoting or resisting tumors by affecting the tumor microenvironment are known as key regulators progression. However, treatments for TNBC (e.g., surgery, chemotherapy radiotherapy) have non-satisfaction’s curative effect so far. This article reviews different types TILs research progress adoptive cell therapy, aiming provide new therapeutic approaches TNBC.

Язык: Английский

Процитировано

15